Company profile: OXGENE
1.1 - Company Overview
Company description
- Provider of versatile cloning plasmids for research, custom cloning and DNA synthesis, and IP-free products. Offers TESSA technology for scalable, cost-effective AAV manufacturing, high-titre transient rAAV production, cell and gene therapy acceleration services (including CAR-T), cell line development and engineering, and LentiVEX plasmids and cell lines for lentiviral vector production.
Products and services
- LentiVEX Plasmids and Cell Lines: Delivers plasmids and cell lines for lentiviral vector production, offering off-the-shelf and custom plasmids plus cell line development services for various applications, modular
- TESSA: Scalable AAV Production: Uses self-silencing adenoviral vectors to engineer high-yield, high-quality AAV batches without contaminants or transfection, streamlining production scale-up and cost control
- Transient AAV Production: Produces high-titre rAAV using reconfigured Rep-Cap and modified Ad5 helper plasmids with a GMP-banked clonal suspension HEK293 cell line, delivering rapid runs and consistent vector quality
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OXGENE
Translate Bio
HQ: United States
Website
- Description: Provider of biotechnology-driven RNA therapeutics focused on rare diseases, developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Translate Bio company profile →
Interactive Biosoftware
HQ: France
Website
- Description: Provider of software solutions for clinical and research scientists in the human genetics field, focusing on practical software applications for health care and life sciences, particularly molecular biology, serving geneticists and researchers worldwide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Interactive Biosoftware company profile →
Twist Bioscience
HQ: United States
Website
- Description: Provider of synthetic DNA solutions using a semiconductor-based platform for high-throughput, cost-effective manufacturing; customizable gene synthesis; variant libraries; NGS target enrichment panels for viral genome detection and characterization; synthetic RNA controls for diagnostic quality assurance; antibody development against SARS-CoV-2; and comprehensive viral research panels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Twist Bioscience company profile →
Delfi Diagnostics
HQ: United States
Website
- Description: Provider of high-precision, non-invasive blood tests for early cancer detection, including the FirstLook Lung test using DNA fragment patterns; leverages machine learning and fragmentomics to analyze cell-free DNA fragments; and runs the CASCADE-LUNG clinical study to validate blood-based lung cancer screening technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delfi Diagnostics company profile →
AutoGenomics
HQ: United States
Website
- Description: Provider of automated microarray-based multiplex molecular diagnostic platforms and genetic testing tools, including INFINITI System, INFINITI PLUS Analyzer, INFINITI High Throughput System, proprietary BioFilmChip microarrays, and assays such as AvertD for opioid use disorder risk and Factor II-V Leiden for thrombophilia, for disease signature assessment in women's health, cancer and personalized medicine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AutoGenomics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OXGENE
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OXGENE
2.2 - Growth funds investing in similar companies to OXGENE
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OXGENE
4.2 - Public trading comparable groups for OXGENE
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →